BPC-157 Dosage Guide

What Is the Standard BPC-157 Dosage?

Standard dosage is 250-500 micrograms (mcg) daily, administered subcutaneously or intramuscularly. Most users take 250-500mcg once daily in the morning, or split into 250mcg twice daily (morning and evening). Oral doses are higher: 1-2mg daily due to reduced bioavailability. No FDA-approved dose exists—doses are derived from animal research, community experience, and individual optimization.

Animal research used 10 micrograms per kilogram of body weight (10 mcg/kg). For a 70kg (154 lb) human, this converts to 700mcg. However, human doses are typically lower (250-500mcg), suggesting either that humans are more sensitive than rodents or that optimal doses are lower than research protocols. The discrepancy is unresolved; clinical research is needed.

How Was BPC-157 Dosage Determined in Research?

Animal toxicity and efficacy studies used doses ranging from 1-100 mcg/kg, with most efficacy at 10 mcg/kg. Doses higher than 100 mcg/kg sometimes showed diminishing returns or paradoxical effects, suggesting a biological ceiling or possible biphasic dose-response (high doses less effective than moderate doses). This pattern suggests an optimal range rather than a linear dose-response.

Clinical trials in humans have not been conducted (as of 2026), so doses are not clinically validated. Community consensus (based on thousands of individual experiences) has converged on 250-500mcg daily as effective and well-tolerated. This is likely more than theoretical 10 mcg/kg per day per kg body weight but appears safe empirically.

Injectable Dosing Protocols

Starting Dose

Begin at 250mcg once daily. This is conservative, allows assessment of tolerance, and minimizes cost. Most users get benefit at this dose. If inadequate response after 2-4 weeks, increase to 250mcg twice daily (500mcg total), then to 500mcg twice daily (1000mcg total) if still needed. Titration allows optimization without unnecessary high-dose exposure.

Standard Maintenance Dose

250-500mcg daily (most common), either as a single morning dose or split into 250mcg morning and evening. This range covers 95% of users reporting efficacy. Some individuals find 250mcg sufficient; others require 500mcg or higher.

High Dose

500-1000mcg daily (500mcg twice daily). Used for severe injuries, chronic conditions, or individuals who don't respond to standard doses. No evidence shows better results than standard doses; some evidence suggests diminishing returns. Cost is substantially higher. Reserve for justified cases.

Dosing Frequency

Daily dosing is standard. Half-life of BPC-157 is approximately 4 hours in stable form, supporting once or twice-daily dosing. Some users dose every other day or 3-4 times weekly; efficacy at these frequencies is not proven. Daily dosing is recommended for acute injury; less frequent dosing might work for maintenance but is untested.

Oral Dosing Protocols

Oral BPC-157 requires higher doses due to lower bioavailability. Standard oral dose: 500mcg to 1mg twice daily (1-2mg total daily). Some users dose 1-2mg once daily. The equivalent injectable dose (250-500mcg) would be roughly 1-2mg oral (accounting for 5-20% bioavailability).

No data guides optimal oral timing. Some users report better absorption on empty stomach; others prefer with food. Experiment and use whichever feels more effective or convenient.

Body Weight and Dosing: Should You Adjust for Weight?

Animal research suggests dose scales with body weight (10 mcg/kg). A 50kg person might theoretically need less than a 100kg person. However, no human weight-response data exists. Most users do not adjust for weight; a 50kg and 100kg user both typically take 250-500mcg. If you are significantly lighter (< 50kg) or heavier (> 120kg), consider modest dose adjustment: lighter individuals might start at 125-250mcg; heavier individuals at 375-500mcg.

This is speculative. Standard dosing (250-500mcg regardless of weight) is safer and more practical.

Dose-Response Relationship: Is More Better?

No. Preclinical research shows optimal efficacy at 10 mcg/kg; higher doses sometimes show diminished effects. In community reports, increasing from 250mcg to 500mcg improves efficacy modestly; increasing further (750-1000mcg) shows minimal additional benefit and increases cost. The "dose-response curve" is not linear; there is an optimal range, not an endless dose-dependent improvement.

Recommended approach: start at 250mcg, increase to 500mcg if needed, stop there. Higher doses are not evidence-based and waste money.

Timing: Morning vs Evening Dosing

No evidence differentiates timing. Some users prefer morning to "start the day with healing." Others prefer evening because "healing happens while you sleep." The difference is minimal. Choose the time that's easiest to remember and take consistently. If splitting doses, morning and evening (12 hours apart) is reasonable.

Cycling and Dosing Adjustments

Standard approach: 250-500mcg daily for 8 weeks, then 4-week break. Do not increase dose during the cycle hoping for faster healing; maintain consistent dosing. Do not skip doses, then double-dose the next day to "catch up"—maintain daily dosing. At the end of the cycle, assess results; if inadequate, increase dose in the next cycle and reassess.

What Happens If You Take Too Much BPC-157?

No acute toxicity has been reported even at very high doses (animal studies used up to 100 mcg/kg with no adverse effects). Theoretically, excessive dosing might cause excessive angiogenesis, vasodilation, or other exaggerated biological effects, but this is not documented. If you accidentally took 10x your planned dose, do not panic—serious adverse effects are unlikely. Monitor for side effects (dizziness, nausea, unusual symptoms) and contact poison control or emergency services if you experience severe symptoms.

Special Populations: Dosing Modifications

Elderly (> 70)

Start at 250mcg once daily, increase cautiously. Reduced tolerance for side effects (dizziness, vasodilation) is possible. Monitor blood pressure and symptoms closely.

Renal or Hepatic Impairment

No data exists. Theoretically, impaired clearance might prolong peptide effects. Consider using lower doses or longer intervals. Consult healthcare provider if you have significant kidney or liver disease.

Pregnancy

Avoid. No safety data in pregnancy. Angiogenesis promotion could theoretically affect fetal development. Do not use during pregnancy or nursing.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions

Is there a maximum safe dose?

No formal maximum exists. Animal studies show no toxicity up to 100 mcg/kg (7000mcg for a 70kg human). Human safe maximum is unknown but assumed higher than therapeutic doses. Do not use this to justify taking extreme doses; empirical evidence shows 250-500mcg is optimal, and higher is not better.

If my injury isn't improving at 250mcg after 4 weeks, should I increase?

Maybe. After 4 weeks, some improvement should be visible (reduced pain, decreased swelling). If none, either BPC-157 isn't helping (non-responder) or dose is inadequate. Increase to 500mcg and reassess after another 4 weeks. If still no improvement, BPC-157 may not work for you—discontinue and try other approaches.

Can I dose BPC-157 every other day instead of daily?

Not recommended. Half-life is 4 hours; every-other-day dosing would mean 44+ hours between doses—likely subtherapeutic. Daily dosing is standard for efficacy. If cost is a concern, lower the daily dose rather than spacing it out.

Should I take BPC-157 before or after exercise?

Timing relative to exercise has not been studied. Theoretically, dosing after training (when inflammation is high) might provide additive anti-inflammatory benefit. Practically, timing is less important than consistency. Take daily and exercise whenever you prefer.

Can I mix BPC-157 with other peptides at the same dose?

No. If combining peptides, reduce each to 50% of standard dose. Additive effects of multiple peptides are unknown. Starting at lower doses minimizes risk. Consult provider before combining multiple research substances.